248 related articles for article (PubMed ID: 9373789)
1. Comparative in vitro activity of cefepime against nosocomial isolates.
Sofianou D; Tsoulfa S; Kontodimou L; Polydorou F; Malaka E
J Chemother; 1997 Oct; 9(5):341-6. PubMed ID: 9373789
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of Ro 09-1428, a novel cephalosporin with a catechol moiety.
Qadri SM; Ayub A; Ueno Y; Saldin H
Clin Ther; 1992; 14(4):562-9. PubMed ID: 1525790
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus.
Tallis E; Rudensky B; Attias D; Raveh D; Schlesinger Y; Yinnon AM
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):121-6. PubMed ID: 10579092
[TBL] [Abstract][Full Text] [Related]
5. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
Tumah H
Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
[TBL] [Abstract][Full Text] [Related]
6. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of BRL 36650, a new penicillin.
Van Landuyt HW; Lambert A; Boelaert J; Gordts B
Antimicrob Agents Chemother; 1986 Feb; 29(2):362-6. PubMed ID: 3087281
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates.
Giamarellos-Bourboulis EJ; Grecka P; Tsitsika A; Tympanidou C; Giamarellou H
Diagn Microbiol Infect Dis; 2000 Mar; 36(3):185-91. PubMed ID: 10729661
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
[TBL] [Abstract][Full Text] [Related]
10. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
Xu Y; Chen M; Biedenbach DJ; Deshpande LM; Jones RN
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):135-42. PubMed ID: 10579094
[TBL] [Abstract][Full Text] [Related]
12. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
13. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group.
Pfaller MA; Jones RN; Doern GV
Diagn Microbiol Infect Dis; 1998 Jan; 30(1):45-52. PubMed ID: 9488831
[TBL] [Abstract][Full Text] [Related]
14. Activity of cefepime against nosocomial blood culture isolates.
Qadri SM; Cunha BA; Ueno Y; Abumustafa F; Imambaccus H; Tullo DD; Domenico P
J Antimicrob Chemother; 1995 Sep; 36(3):531-6. PubMed ID: 8830018
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.
Hebeisen P; Heinze-Krauss I; Angehrn P; Hohl P; Page MG; Then RL
Antimicrob Agents Chemother; 2001 Mar; 45(3):825-36. PubMed ID: 11181368
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of the in-vitro activity of cefepime and other cephalosporins.
Lim VK; Halijah MY
Malays J Pathol; 1993 Jun; 15(1):65-8. PubMed ID: 8277793
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.
Frei R; Jones RN; Pignatari AC; Yamane N; Marco F; Hoban DJ
Diagn Microbiol Infect Dis; 1994 Mar; 18(3):167-73. PubMed ID: 7924209
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.
Neu HC; Chin NX; Huang HB
Antimicrob Agents Chemother; 1993 Mar; 37(3):566-73. PubMed ID: 8460925
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
Weinstein RA; Nathan C; Delzell D; Kabins SA
Chemioterapia; 1987 Oct; 6(5):315-8. PubMed ID: 3123078
[TBL] [Abstract][Full Text] [Related]
20. Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.
Vahaboglu H; Saribaş S; Akbal H; Ozturk R; Yucel A
J Antimicrob Chemother; 1998 Aug; 42(2):269-70. PubMed ID: 9738851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
